Severe allergic reactions to Moderna vaccine appear rare: CDC report
Send a link to a friend
[January 23, 2021]
(Reuters) - Severe allergic reactions to Moderna Inc's coronavirus
vaccine appear to be quite rare, the U.S. Centers for Disease Control
and Prevention (CDC) said on Friday, after over 4 million people had
received their first dose.
|
Based on the data, the CDC said anaphylaxis, a life-threatening
allergic reaction, occurred at a rate of 2.5 cases per 1 million
shots administered.
The agency cautioned that the risk of anaphylaxis was difficult to
compare to non–COVID-19 vaccines because it is still so early in the
vaccination program.
As of Jan. 10, there were 10 cases of anaphylaxis reported among
4.04 million people who received their first doses of Moderna's
two-shot vaccine, according to the agency's Morbidity and Mortality
Weekly Report. (https://bit.ly/3973U4N)
The CDC said the characteristics of severe allergic reactions to
Moderna's vaccine were similar to those reported with the COVID-19
vaccine from Pfizer Inc and partner BioNTech SE.
Earlier this month, the CDC reported severe allergic reactions to
the Pfizer/BioNTech shot occurred at a rate of 11.1 per 1 million
vaccinations.
[to top of second column] |
For both vaccines, symptoms
presented within minutes after vaccination and
were more common among women. Many of those who
suffered anaphylaxis after receiving either
vaccine had a history of allergies or allergic
reactions, and several had an anaphylaxis
episode in the past, the CDC said.
The agency said locations administering COVID-19
vaccines should screen recipients, have
necessary supplies and staff members to manage
anaphylaxis, and immediately treat suspected
cases with an epinephrine injection, the same
drug in EpiPens.
(Reporting by Vishwadha Chander in Bengaluru and
Julie Steenhuysen in Chicago; Editing by
Caroline Humer and Bill Berkrot)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |